 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- |||| LIV-GAMMA SN Inj.10% (SKP-0110) / SK Discovery
New P3 trial: A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Oct 5, 2022
P3, N=34, Completed, Sponsor: SK Plasma Co., Ltd.